Saturday, September 6, 2025
  • Advertise
  • Recruitment
  • Contact us:
  • Register
Irish Pharmacy News
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
  • News
    • Latest
    • Community Pharmacy
  • Learning
    • CPD
    • Features
    • Team Training
    • Research
  • Magazines
  • OTC
    • OTC Awards
    • Product News
  • Awards
    • Irish Pharmacy Awards 2024
    • Awards News
  • HPN
  • Log In
  • Register
No Result
View All Result
Irish Pharmacy News

Researchers discover potential new therapy for chemotherapy-resistant breast cancer

Robyn Maginnis by Robyn Maginnis
20 January 2021
in Developments, Research
0
Researchers discover potential new therapy for chemotherapy-resistant breast cancer

23/05/2016, RCSI Headshots for brochure, 123 St. Stephen's Green, Dublin 2 (Picture: Lafayette Photography)

Scientists have discovered a molecule that can selectively kill cells of a hard-to-treat subtype of breast cancer, which could lead to a new therapy.

The study, led by researchers at RCSI University of Medicine and Health Sciences, is published in the current edition of Science Advances.

Triple negative breast cancer is a subtype of breast cancer which is mainly treated with chemotherapy. Unfortunately, up to 70% of patients with this form of breast cancer develop resistance to treatment.

The researchers tested different molecules to see if they could selectively kill the cells of this type of breast cancer while sparing normal cells. They found that a specific molecule, BAS-2, was able to do this.

“Our aim now is to develop the small molecule into a more drug-like compound and to assess if we can harness the new function for potentially improved treatment of patients,” said Dr Tríona Ní Chonghaile, the study’s corresponding author and an RCSI lecturer in Physiology and Medical Physics.

To better understand how the molecule killed the cells, the researchers confirmed that it inhibited an enzyme called HDAC6. Using state-of-the art mass spectrometry, the researchers identified, for the first time, that HDAC6 plays a key role in altering energy in these cancer cells.

The work was funded by the Wellcome Trust Seed Award, L’Oreal-UNESCO For Women in Science Programme and Science Foundation Ireland’s Frontiers for the Future Programme. In addition to those from RCSI, the work was carried out by researchers from the UCD Conway Institute of Biomedical and Biomolecular Sciences, NYU Langone Medical Center, Penn State University, the Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber Cancer Institute at Harvard Medical School.

With the help of RCSI’s Office of Research and Innovation, the researchers have submitted a patent around this work and are seeking industry partners to further develop this treatment.

Tags: chemotherapy irelandireland pharmacyIrish Pharmacy Newsmedicine ireland
Previous Post

Topic Team Training – Don’t get Down

Next Post

New free Toolkit launched to support those delivering end-of-life care as COVID-19 continues to surge

Next Post
New free Toolkit launched to support those delivering end-of-life care as COVID-19 continues to surge

New free Toolkit launched to support those delivering end-of-life care as COVID-19 continues to surge

Leave a Reply

Your email address will not be published. Required fields are marked *

Four UCD researchers receive ERC Starting Grants for groundbreaking research projects

Four UCD researchers receive ERC Starting Grants for groundbreaking research projects

4 September 2025
EUROPEAN COMMISSION AUTHORISES TWICE-YEARLY LENACAPAVIR FOR HIV  PREVENTION (brand name YEYTUO®) 

EUROPEAN COMMISSION AUTHORISES TWICE-YEARLY LENACAPAVIR FOR HIV  PREVENTION (brand name YEYTUO®) 

4 September 2025
Back to school: Expert guidance from the HSE for a smoother start to the school year

Back to school: Expert guidance from the HSE for a smoother start to the school year

22 August 2025

RECOMMENDED NEWS

McCabes Pharmacy Announced as Exclusive Pharmacy Partner to Athletics Ireland and Title Sponsor of “Fit for Life” Programme

McCabes Pharmacy Announced as Exclusive Pharmacy Partner to Athletics Ireland and Title Sponsor of “Fit for Life” Programme

4 months ago
Vitamin B12 deficiency increases risk of depression: TILDA study

Vitamin B12 deficiency increases risk of depression: TILDA study

4 years ago
Michaela Hagenhofer Appointed General Manager, Johnson & Johnson Innovative Medicine Ireland – Commercial Operations

Michaela Hagenhofer Appointed General Manager, Johnson & Johnson Innovative Medicine Ireland – Commercial Operations

1 year ago

Signposting Patients with Wet AMD

5 years ago
Tweets by Irish_PharmNews

Quick links

  • About
  • Advertise
  • Careers
  • Contact us

Other info

  • Contact us
  • Register for Digital Magazines
  • Privacy Policy
  • About
  • Advertise
  • Careers
  • Contact us

© 2024 IPN

  • Login

    Forgot password? | Register

    Register

    Registration confirmation will be emailed to you.

    Login | Forgot password?

    Reset Password

    Please enter your username or email address. You will receive a link to create a new password via email.

    Login

Login

Register

Forgotten Password?

Register | Lost your password?
| Back to Login
No Result
View All Result
  • News
  • Learning
  • Other
    • Conferencing
    • Developments
    • Product News
    • Profiles
    • Research
  • Digital Magazines (IPN Online Issues Older Issue Tabs)
  • Awards

© 2024 IPN